H1B Salary Data

Home › Employers › IVIEW Therapeutics Inc.

IVIEW Therapeutics Inc.: H-1B salaries and sponsorship

IVIEW Therapeutics Inc. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 4. Median offered salary: $101,750.

Applications (LCAs)4
Certified4
Employer addressCranbury, NJ
H-1B dependent employerNo
Median offered salary$101,750
Middle half of salaries$89,625–$103,500
10th–90th percentile$70,950–$103,500

Does IVIEW Therapeutics Inc. sponsor H-1B visas?

IVIEW Therapeutics Inc. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 24, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Research Scientist3$103,500
Business Operations Associate1$58,500

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20252$103,500
FY20262$79,250

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Business Operations Associate$58,500
Level I
Cranbury, NJApr 24, 2026Oct 1, 2026Certified
Research Scientist$100,000
Level III
Cranbury, NJApr 24, 2026Oct 1, 2026Certified
Research Scientist$103,500
Level III
Cranbury, NJMar 21, 2025Sep 20, 2025Certified
Research Scientist$103,500
Level III
Cranbury, NJMar 14, 2025Mar 14, 2025Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).